IPSEN – Buy-back programme – Art 5 of MAR – Week 30 – 2026
Aggregated presentation by day and by market
| Weekly report on share repurchases from 20th July to 24th July 2026 | ||||||
| Name of the Issuer | Identify code of the Issuer | Transaction day | Identify code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/07/2026 | FR0010259150 | 2 006 | 160,4222 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 21/07/2026 | FR0010259150 | 1 504 | 159,8955 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 23/07/2026 | FR0010259150 | 3 500 | 161,4505 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 24/07/2026 | FR0010259150 | 6 602 | 157,7301 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 24/07/2026 | FR0010259150 | 149 | 156,8597 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 24/07/2026 | FR0010259150 | 169 | 156,8911 | AQEU |
| TOTAL | 13 930 | 159.2669 | ||||
Attachment

IPSEN – Buy-back programme – Art 5 of MAR – Week 30 – 2026
Aggregated presentation by day and by market
| Weekly report on share repurchases from 20th July to 24th July 2026 | ||||||
| Name of the Issuer | Identify code of the Issuer | Transaction day | Identify code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 20/07/2026 | FR0010259150 | 2 006 | 160,4222 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 21/07/2026 | FR0010259150 | 1 504 | 159,8955 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 23/07/2026 | FR0010259150 | 3 500 | 161,4505 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 24/07/2026 | FR0010259150 | 6 602 | 157,7301 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 24/07/2026 | FR0010259150 | 149 | 156,8597 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 24/07/2026 | FR0010259150 | 169 | 156,8911 | AQEU |
| TOTAL | 13 930 | 159.2669 | ||||
Attachment

Related stories
Retrouver la lumière : le parcours de Rajminder Malhi
Quand les acides biliaires prennent une dimension plus large : comment la biologie de la cholestase transforme la recherche sur les maladies hépatiques rares
Tester l’hypothèse : un pilote ciblé sur l’IA dans le domaine de la santé
Related Press Releases
Ipsen provides update on Phase III BOLD trial in biliary...
Ipsen – Corrective statement amending the monthly disclosure of the...
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset...
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – June 2026 – Monthly information relative to the...
Ipsen – Half year statement – 2026 06 30
IPSEN – Buy-back programme – Art 5 of MAR –...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus...